TAIWANESE HEALTH AND RESEARCH DELEGATION VISIT PARATUS CLINICAL TRIAL SITE IN CANBERRA Visit fosters greater collaboration and experience of clinical trial execution in public and private health settings best practice
With
Matt Clacy,
Founder & Chief Commercial Officer
Paratus Clinical
Dr Amber Leah,
Principal Investigator & Medical Director
Paratus Clinical
Professor Chun-Jen Huang,
Dean of Office of Human Research
Taipei Medical University & Taipei Municipal Wanfang Hospital
Taiwan
Professor Pin-Kuei Fu,
Director, Clinical Research Center
Taichung Veterans General Hospital
Taiwan
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Canberra | September 2025
In late August 2025, a Taiwanese delegation comprising government officials from the Taiwanese FDA, various governmental groups, and physicians and researchers from across Taiwan, visited Paratus Clinical’s trial site in Canberra. Their objective was to explore both the differences and similarities between the clinical research ecosystems of Taiwan and Australia.
Throughout the discussions, the delegation learned about the processes involved in initiating research, the regulatory hurdles that must be navigated, and the practicalities of conducting clinical trials in both public and private sectors.
Paratus Clinical specialises in a range of clinical trials, from Phase I to Phase III, including vaccine studies and treatments across primary care areas such as asthma, diabetes, and cardiometabolic health, as well as outpatient specialties like dermatology and oncology.
The conversations also addressed the distinctions between inpatient and outpatient care, focusing on startup timelines, regulatory requirements, and patient recruitment strategies. Notably, the delegation found a reassuring number of similarities in clinical practice between the two countries.
Matt Clacy, recognised the potential benefit of fostering greater collaboration between public and private sectors in Australia, a practice that is more prevalent in Taiwan and advantageous for patient care and the healthcare system overall.
Source: Written by AUDIENCED
-
Spinal implant technology eyes global opportunity
Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
-
Addressing Pharmacy challenges at home and abroad
Paul Sinclair’s progression through the ranks of the International Pharmaceutical Federation (FIP) demonstrates the impact and influence he’s had in representing the pharmacy profession on a global scale. In this Australian Health Journal interview, Paul talks about the 4 themes in the upcoming FIP Congress in Brisbane this month. He also talks about the challenges facing pharmacy with remuneration, professional service delivery and the workforce coming out of the COVID era.
-
Psychiatrists to discuss connectedness at RANZCP 2023 Congress
Next week, at the Perth Convention and Exhibition Centre, The Royal Australian and New Zealand College of Psychiatrists (RANZCP) meet for the RANZCP 2023 Congress on the theme of “New Horizons: Connected Futures”
Australian Health Journal spoke to current President-Elect Dr Elizabeth Moore and soon to be President, RANZCP about the Congress, as well as the recent Federal Budget announcements around mental health funding.
